People · Operator
Named in public records as an officer, director or promoter · active 2018–2022 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| CARISMA Therapeutics Inc. | — | Biotechnology | Series C | $95.0M | $1.3B | 2018 |
| Innervace, Inc. | — | Biotechnology | Series A | $10.0M | $131.2M | 2022 |
Althea Stillman at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Althea Stillman on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Jonathan Leff | 1 | 11 |
| Briggs Morrison | 1 | 8 |
| Michael Heffernan | 1 | 5 |
| Bruce Peacock | 1 | 5 |
| Michael Poisel | 1 | 4 |
| Eran Nadav | 1 | 4 |
| Steven Kelly | 1 | 4 |
| Margarita Chavez | 1 | 4 |
| Chidozie Ugwumba | 1 | 3 |
| Regina Hodits | 1 | 2 |
| Dora Mitchell | 1 | 1 |
| Jacob Gunterberg | 1 | 1 |
| Hy Levitsky | 1 | 1 |
| David Greenwald | 1 | 1 |
| Nader Halim | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.